Indian markets are expected to see higher volatility after Shri Mahavir Jayanti holiday on Thursday. US markets registered strong rally on Wednesday but Thursday was disappointing as markets dropped. Indian markets could see higher levels in today's session but due to yesterday's holiday, the global markets rally on Thursday could be missed. While the trading floor takes a ceremonial break, the global financial landscape continues to churn. From TCS's Q4 earnings and Infosys's European expansion to escalating US-China trade tensions, the financial community is grappling with developments of far-reaching consequence. In the backdrop, emerging updates from pharma, energy, and telecom sectors are setting the tone for the days ahead.

TCS Reports Mixed Q4 Performance; Declares Interim Dividend

Tata Consultancy Services (TCS) posted a marginal decline in profits for the fourth quarter.

Profit declined 1.3% QoQ to Rs 12,224 crore, down from Rs 12,380 crore.

Revenue rose 0.8% QoQ to Rs 64,479 crore.

EBIT stood at Rs 15,601 crore, while operating margins compressed by 30 basis points to 24.2%.

The IT major announced an interim dividend of Rs 30 per share.

Total contract value reached $12.2 billion, reflecting resilient demand despite macro uncertainty.

Bharti Hexacom Pauses Indus Towers Deal on Governance Grounds

Bharti Hexacom, under advisement from major stakeholder Telecommunications Consultants India Ltd (TCIL), has suspended the ongoing infrastructure divestment deal with Indus Towers. The move underscores TCIL’s push for renewed transparency and governance. A fresh process, aligned with corporate best practices, is now underway.

Infosys Deepens European Roots via AIB Alliance

Infosys has fortified its European footprint by extending its partnership with Allied Irish Banks (AIB). The strategic engagement includes AI-driven tools, agile practices, and application development, signaling the company’s continued pivot towards high-margin digital transformation services.

Aurobindo Pharma Pushes Ahead with Denosumab Biosimilar

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has concluded Phase 1 trials for its denosumab biosimilar (BP16). The biologic specifically targets the RANK ligand, a key player in osteoclast activity linked to bone degeneration. This advancement strengthens Aurobindo's position in the global biosimilar market.

BHEL Taps Italian Expertise for Fertilizer Sector Modernization

Bharat Heavy Electricals Ltd (BHEL) has inked a Memorandum of Understanding (MoU) with Italy’s Nuovo Pignone International S.r.l. The agreement involves a 50:50 financial share for compressor revamp projects aimed at India’s fertilizer plants—an industry pivotal to agricultural resilience.

Coromandel Enhances Phosphate Supply Chain with Ma’aden Partnership

In a significant agribusiness development, Coromandel International has renewed its collaboration with Saudi Arabian mining giant Ma’aden. This MoU secures timely supply of DAP and NPK fertilizers, easing seasonal logistics pressures and enhancing Coromandel’s backend security.

Bank of India Reduces Lending Rates in Sync with RBI Easing

Post the RBI’s decision to lower the repo rate by 25 basis points to 6%, Bank of India has adjusted its Repo-Based Lending Rate (RBLR) to 8.85%, down from 9.1%. This move is anticipated to boost credit offtake and spur consumption-led sectors.

Tata Steel Plans Major Restructuring in Europe

Tata Steel Nederland has initiated consultations on a transformational restructuring plan, proposing to trim around 1,600 managerial and support roles. The overhaul is aimed at modernizing operations and optimizing capital allocation, though labor negotiations are expected to be complex.

Sanofi India’s Leadership Shuffle: Hrosz Steps Aside

Rodolfo Hrosz, Managing Director of Sanofi India, will step down effective April 30. He will assume a non-executive director role starting May 1, suggesting continuity in strategic oversight while paving the way for leadership renewal.

Sun Pharma Wins Legal Battle; Set to Launch LEQSELVI

In a significant legal victory, Sun Pharmaceutical Industries has had the injunction against LEQSELVI lifted by the US Court of Appeals. The company now eyes an imminent US launch of the deuruxolitinib-based treatment for skin cancer, a key addition to its specialty portfolio.

Biocon Scores FDA Nod for Avastin Biosimilar

Biocon Biologics has received FDA approval for Jobevne, a biosimilar to Avastin (bevacizumab). The molecule is crucial in treating multiple cancers, reaffirming Biocon’s R&D prowess and commitment to expanding access to life-saving biologics.

GAIL Nears Completion of Energy Pipeline Backbone

GAIL (India) announced that 97.6% of the Jagdishpur–Haldia–Bokaro–Dhamra pipeline—also called 'Urja Ganga'—has been completed. Currently, 12.26 million standard cubic meters per day of natural gas is being dispatched to eastern and northeastern India. Commercial operations are live on 96.6% of the route, marking a milestone in energy accessibility.